This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Home Hemodialysis Patients Urge Medicare To Fix HHD Training Reimbursement

WASHINGTON, March 20, 2013 /PRNewswire/ -- In honor of National Kidney Month, current and former dialyzors with Hemodialysis at Home:  A Better Way for a Better Life , a NxStage Medical, Inc. (NASDAQ: NXTM) sponsored project, gathered in Washington, D.C. today to urge the Centers for Medicare and Medicaid Services (CMS) to remove barriers limiting access to home hemodialysis (HHD). Specifically, the group urged CMS to fix its current payment policy to provide adequate reimbursement for the up-front costs associated with HHD training.

(Logo: )

"Home hemodialysis works. It gives me the freedom and flexibility to live a more normal life on dialysis," said Kathe Lebeau, a patient currently doing HHD with the NxStage® System Oneā„¢ who made the trip to D.C. "Unfortunately, access to HHD is severely limited today with less than 2% of patients doing HHD. We are asking CMS to give more patients access to HHD by updating its current payment structure to provide adequate reimbursement for HHD training. It's a simple fix that would make a big difference for dialysis patients across the country."

While in D.C., the group met with their elected representatives as well as CMS representatives to discuss the benefits of HHD and barriers that are limiting access for patients. The group asked for help in making sure those barriers are removed. 

This 'call to action' comes just days after Reps. Jim McDermott and Tom Marino sent letters to Congressional representatives urging them to sign onto a bi-partisan letter asking Health and Human Services Secretary Sibelius and the Centers for Medicare & Medicaid Services to update home hemodialysis training payments.  In their letter, the Congressional Kidney Caucus co-chairs said, "dialysis patients should be aware of and have access to the treatment option that they and their physicians think best."

In recent years, peer reviewed articles have reported on the clinical and quality of life benefits, and lower mortality experienced by patients on more frequent home hemodialysis when compared with three-times-weekly in-center therapy. The literature strongly supports the meaningful benefits possible with more frequent home hemodialysis. Yet, many patients aren't adequately informed about all of their treatment options and more than 90% of patients undergoing dialysis in the United States are doing three-times-weekly in-center therapy. That's despite the fact that in a recent survey, more than 90% of nephrologists said they would choose home dialysis over in-center dialysis for themselves or a family member, with HHD being the preferred option. 

Supporters of  Hemodialysis at Home:  A Better Way For a Better Life are actively urging CMS to update its current payment structure to provide adequate reimbursement for the up-front costs associated with HHD training to expand patient access to HHD.

About Hemodialysis at Home:  A Better Way For a Better Life

Hemodialysis at Home: A Better Way For A Better Life brings together dialyzors, care partners, physicians, nurses, patient advocates, and other renal professionals from across the country who believe patients need to have better access to and more awareness of the improved quality of life reported to be made possible by home dialysis technology.  Hemodialysis at Home: A Better Way For A Better Life is a project of NxStage Medical, Inc.  For more information, please visit

About the NxStage System One

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs